12:54:17 EST Mon 24 Feb 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 21,238,831
Close 2019-03-27 C$ 0.97
Recent Sedar Documents

Trillium to present on Sting at meeting in Atlanta

2019-03-27 17:11 ET - News Release

Mr. Zezhou Wang reports

TRILLIUM THERAPEUTICS TO UNVEIL ITS STING AGONIST PROGRAM AT THE AACR ANNUAL MEETING 2019

Trillium Therapeutics Inc. will be presenting preclinical data from its previously undisclosed STING agonist program at the annual meeting of the American Association for Cancer Research. The meeting will be held March 29 to April 3 in Atlanta, Ga. Details of the poster presentation are listed below.

Title:  "Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice"

Presenter:  Zezhou Wang, PhD, Trillium Therapeutics

Date and time:  April 2, 2019, from 1 p.m. to 5 p.m. ET

Location:  Georgia World Conference Center, Poster Section 12

Abstract No.: 3854

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.

© 2020 Canjex Publishing Ltd. All rights reserved.